Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 12/03 11:30:38 am
73.57 CHF   -0.31%
12/03Bryan Garnier Downgrades Novartis to Neutral from Buy
MT
12/03NOVARTIS AG : UBS reaffirms its Neutral rating
MD
12/03NOVARTIS AG : Sell rating from JP Morgan
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
74.24(c) 73.44(c) 74.24(c) 73.8(c) 73.57(c) Last
3 899 659 7 641 732 4 203 828 4 873 177 3 104 509 Volume
-0.64% -1.08% +1.09% -0.59% -0.31% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 52 117 M - -
Net income 2021 15 146 M - -
Net Debt 2021 20 532 M - -
P/E ratio 2021 12,6x
Yield 2021 4,10%
Sales 2022 54 039 M - -
Net income 2022 10 712 M - -
Net Debt 2022 16 147 M - -
P/E ratio 2022 16,8x
Yield 2022 4,23%
Capitalization 179 B 179 B -
EV / Sales 2021 3,83x
EV / Sales 2022 3,62x
Nbr of Employees 108 000
Free-Float 85,7%
More Financials
Company
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and... 
Read more
Sector
Pharmaceuticals
Calendar
12/09Presentation
More about the company
Ratings of Novartis AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about NOVARTIS AG
12/03Bryan Garnier Downgrades Novartis to Neutral from Buy
MT
12/03NOVARTIS AG : UBS reaffirms its Neutral rating
MD
12/03NOVARTIS AG : Sell rating from JP Morgan
MD
12/03Drugmakers cut prices by 62% on average to get China state insurance listing
RE
12/02Novartis Mulls Bolt-On Acquisitions
CI
12/02GLOBAL MARKETS LIVE : Hermès, Walt Disney, Apple, Novartis, Square...
12/02MarketScreener's World Press Review - December 2, 2021
12/02Novartis Sees 4% Compound Annual Growth in Sales Through 2026
MT
12/02EUROPEAN MIDDAY BRIEFING - Stocks Tumble Again in -2-
DJ
12/02NORTH AMERICAN MORNING BRIEFING : Stock Futures -2-
DJ
12/02Novartis Says Top Drugs Should Fuel Sales Growth Through 2026
DJ
12/02Novartis expects new drugs to boost sales by at least 4% until 2026
RE
12/02Novartis Expects Over 4% Sales Growth Through To 2026
MT
12/02Novartis, UCB Partner to Jointly Develop, Commercialize Parkinson's Disease Drugs
MT
12/02Novartis' Cosentyx Cuts Inflammatory Lesions in Two Late-Stage Skin Disorder Studies
MT
More news
News in other languages on NOVARTIS AG
12/03BOURSE ZURICH : le SMI perd son élan dans le sillage de Wall Street
12/03AKTIEN SCHWEIZ SCHLUSS : Nullsummenspiel - Gewinne schmelzen am Nachmittag ab
12/03Bel20 sluit week lager
12/03Aktien Schweiz wenig verändert - Aktie von Swiss Life gesucht
12/03KBC Securities verhoogt koersdoel UCB
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Analysis
Drugmakers cut prices by 62% on average to get China state insurance listing
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 80,15 $
Average target price 97,47 $
Spread / Average Target 21,6%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-12.05%179 058
JOHNSON & JOHNSON1.27%419 583
ROCHE HOLDING AG17.62%341 364
PFIZER, INC.44.09%304 610
NOVO NORDISK A/S64.51%244 010
ELI LILLY AND COMPANY47.55%222 641